GeoVax Labs Inc.
1256 Briarcliff Road
254 articles with GeoVax Labs Inc.
GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology
GeoVax Labs, Inc. announced its financial results for the quarter ended September 30, 2018, and provided an update on its research and development programs.
Plug & Play Platform Continues to be Recognized for Distinct Benefits
New Study Suggests Zika Virus Eradication in the Americas May Become Impossible, Making the Need for a Vaccine Even More Critical
GeoVax Comments on New Study Conducted in Brazil
GeoVax Announces Further Positive Results of its HIV Preventive Vaccine Program at International HIV Research Conference
Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response
Comprehensive Review Published in the Peer-Reviewed Journal, Clinical Pharmacology and Therapeutics
GeoVax Labs, Inc. today is observing National Latinx AIDS Awareness Day, a time to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on Hispanics/Latinos in the United States.
GeoVax Labs, Inc. today is observing National Gay Men’s HIV/AIDS Awareness Day
GeoVax Labs, Inc. announced today that the U.S. Department of Defense (DoD) has awarded the Company a $2,442,307 cooperative agreement in supportof its novel Lassa Fever (LF) vaccine development program.
GeoVax Labs Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on recent age-associated HIV infection trends observed in the United States.
Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis
GeoVax Labs, Inc. announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will deliver a talk during the 12th Vaccine Congress, organized by Elsevier and Vaccine journal, being held September 16-19, 2018 in Budapest, Hungary.
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced the strengthening of its scientific team through the addition of two PhD-level scientists.
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a paper published by Iampietro et al, from the Department of Pathology, University of Texas Medical Branch at Galveston, Texas, in The Journal of Infectious Diseases, concerning new findings on how the Ebola virus (EBOV) disables the host immune system and spreads infection.
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with PharmaJet, Inc., on the evaluation of PharmaJet’s needle-free injection system for administration of GeoVax’s Zika vaccine.
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement.
GeoVax's immuno-oncology program is based on its Modified Vaccinia Ankara Virus-Like Particle platform
GeoVax Labs today announced that the HIV Vaccine Trials Network has closed enrollment for the phase 1 human clinical trial evaluating late boosts of GeoVax's preventive vaccine (GOVX-B11) for clade B HIV.
Dr. Guirakhoo will discuss GeoVax's vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated.
GeoVax reported a net loss of $588,787 ($0.01 per share) for the three months ended September 30, 2017, compared to $464,200 ($0.01 per share) for the same period in 2016.